PPARα and dyslipidemia

被引:173
作者
Duval, Caroline [1 ]
Muller, Michael [1 ]
Kersten, Sander [1 ]
机构
[1] Wageningen Univ, Nutr Metabol & Genom Grp & Nutrigenom Consurtium, NL-6700 EV Wageningen, Netherlands
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2007年 / 1771卷 / 08期
关键词
dyslipidemia; peroxisome proliferator activated receptor; high density lipoprotein; very low density lipoprotein;
D O I
10.1016/j.bbalip.2007.05.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dyslipidemia is defined by abnormal levels of plasma lipoproteins. Several different types of dyslipidernia can be distinguished. An important group of drugs used in the treatment of dyslipidernia are the fibrates. Fibrates serve as agonists for the peroxisome proliferator-activated receptor alpha (PPAR(x), a ligand-activated transcription factor that belongs to the superfamily of nuclear hormone receptors. By binding to response elements mostly present in the promoter of target genes, PPAR alpha governs the expression of numerous genes involved in a variety of metabolic processes. Activation of PPAR(x results in a reduction of plasma TG levels, which is achieved by: (1) induction of genes that decrease the availability of TG for hepatic VLDL secretion, and (2) induction of genes that promote lipoprotein lipase-mediated lipolysis of TG-rich plasma lipoproteins. The stimulatory effect of PPAR alpha on plasma HDL levels in humans, which is opposite to what is observed in mice, appears to be mainly mediated via increased production of APOA1 and APOA2, the apolipoprotein constituents of HDL. Apart from its major actions outlined above, PPARa. modulates lipoprotein metabolism in several other ways, mostly via direct up-regulation of specific PPAR(x target genes. By taking into account novel insights into the metabolism of plasma lipoproteins and by considering the latest information on PPAR alpha-dependent gene regulation, a fresh perspective on the molecular mechanisms underlying the plasma lipoprotein modulating effect of PPAR alpha is presented. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:961 / 971
页数:11
相关论文
共 118 条
[51]   Transgenic angiopoietin-like (Angptl)4 overexpression and targeted disruption of Angptl4 and Angptl3:: Regulation of triglyceride metabolism [J].
Köster, A ;
Chao, YB ;
Mosior, M ;
Ford, A ;
Gonzalez-De Whitt, PA ;
Hale, JE ;
Li, DS ;
Qiu, YB ;
Fraser, CC ;
Yang, DD ;
Heuer, JG ;
Jaskunas, SR ;
Eacho, P .
ENDOCRINOLOGY, 2005, 146 (11) :4943-4950
[52]  
Lacquemant C, 2000, DIABETES METAB, V26, P393
[53]   Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway [J].
Lehmann, JM ;
Kliewer, SA ;
Moore, LB ;
SmithOliver, TA ;
Oliver, BB ;
Su, JL ;
Sundseth, SS ;
Winegar, DA ;
Blanchard, DE ;
Spencer, TA ;
Willson, TM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (06) :3137-3140
[54]   A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response:: The PPARα-null mouse as a model of fatty acid oxidation disorders [J].
Leone, TC ;
Weinheimer, CJ ;
Kelly, DP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7473-7478
[55]   New insights into the regulation of HDL metabolism and reverse cholesterol transport [J].
Lewis, GF ;
Rader, DJ .
CIRCULATION RESEARCH, 2005, 96 (12) :1221-1232
[56]   Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and β [J].
Li, AC ;
Binder, CJ ;
Gutierrez, A ;
Brown, KK ;
Plotkin, CR ;
Pattison, JW ;
Valledor, AF ;
Davis, RA ;
Willson, TM ;
Witztum, JL ;
Palinski, W ;
Glass, CK .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (11) :1564-1576
[57]   Influence of peroxisome proliferator-activated receptor α agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48 [J].
Lindén, D ;
Lindberg, K ;
Oscarsson, J ;
Claesson, C ;
Asp, L ;
Li, L ;
Gustafsson, M ;
Borén, J ;
Olofsson, SO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (25) :23044-23053
[58]  
Lindén D, 2001, J LIPID RES, V42, P1831
[59]   LIPOPROTEIN COMPOSITION CHANGES INDUCED BY FENOFIBRATE IN DYSBETALIPOPROTEINEMIA TYPE-III [J].
LUSSIERCACAN, S ;
BARD, JM ;
BOULET, L ;
NESTRUCK, AC ;
GROTHE, AM ;
FRUCHART, JC ;
DAVIGNON, J .
ATHEROSCLEROSIS, 1989, 78 (2-3) :167-182
[60]   EFFECTS OF FENOFIBRATE ON HIGH AND LOW-DENSITY LIPOPROTEIN METABOLISM IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
MALMENDIER, CL ;
DELCROIX, C .
ATHEROSCLEROSIS, 1985, 55 (02) :161-169